This analysis evaluates longitudinal outcomes from multiple CME activities on relapsed/refractory multiple myeloma conducted between 2021–2025. Objectives included identifying persistent educational gaps in BCMA-targeted therapy sequencing, management of ADC-associated ocular toxicities, and disparities in care. Methods involved pre-/post-assessments, subgroup analysis by specialty and practice setting, and comparative evaluations over time. Results revealed statistically significant gains in knowledge and confidence across all learner types, yet persistent gaps remained—especially among oncologists for interpreting pivotal trial data and among multidisciplinary teams managing ADC toxicities. Additionally, notable deficits in understanding healthcare disparities and clinical trial access were identified. These insights underscore the need for multidisciplinary, targeted education and highlight replicable strategies for designing CME that drives sustained impact across diverse oncology care teams.
Learning Objectives:
Identify persistent knowledge gaps in BCMA-targeted therapy sequencing among oncology professionals.
Evaluate learner competence in recognizing and managing ADC-associated toxicities.
Assess improvements and ongoing gaps in understanding healthcare disparities in myeloma care.
